Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma

NCT04525209 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT04525209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04525209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma
Lead sponsor
Ruijin Hospital
Phase
Observational
Overall status
Unknown status
Start date
October 1, 2020
Completion date
December 31, 2022
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tumor tissues and non-tumor tissues from pdac patients were used for genomic and transcriptome sequencing analysis and proteomics and phosphorylated proteomics